Atlas Trials

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Clinical trial NCT03113500 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03113500
Sponsor
City of Hope Medical Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Adult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveAngioimmunoblastic T-Cell LymphomaAnn Arbor Stage II Noncutaneous Anaplastic Large Cell LymphomaAnn Arbor Stage III Noncutaneous Anaplastic Large Cell LymphomaAnn Arbor Stage IV Noncutaneous Anaplastic Large Cell LymphomaEnteropathy-Associated T-Cell LymphomaHepatosplenic T-Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaPeripheral T-Cell Lymphoma, Not Otherwise Specified
Start date
2017-05-25
Primary completion
2021-07-16
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.